RA CAPITAL MANAGEMENT, L.P. sold $146K of HOWL (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 416,911 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.35 ($0.15M total) across 2 trades on 2026-06-17.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jun 22, 2026, 10:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 11:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HOWL
Bearish
medium confidence
Mentioned
$HOWL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HOWLBearishLow
01

Why it matters

Traders may reassess near-term supply/demand dynamics and holder sentiment, but the disclosure alone is unlikely to change fundamentals.

02

Market read

A non-10b5-1 affiliate sale by a 10% owner is a modest sentiment/overhang datapoint for HOWL.

03

What to watch

The filing is indirect and does not specify the reason for sale; also, the $0.35 price level may reflect prevailing microcap trading conditions rather than a new valuation signal.

Relevance 4/10Novelty 5/10Timing: filed 2026-06-22 after-hours; transaction dated 2026-06-17

Background

SEC Form 4 insider transaction: RA Capital Management, L.P. (10% owner) reported an indirect open-market sale of Werewolf Therapeutics shares.

Company-level read

Ticker impact

$HOWLBearishMedium confidence
Context

RA Capital Management, a 10% owner, filed a Form 4 showing an indirect open-market sale of 416,911 HOWL shares at $0.35 on 2026-06-17.

Expected impact

Likely modest negative bias for HOWL shares around the filing window; magnitude depends on broader liquidity/float and whether other holders also sell.

Evidence & confidence

Form 4 is primary-source and the transaction size (~$146k) is meaningful for a small-cap, but it is an indirect sale by an affiliate/owner and not a company fundamental update.

Market effects

Limited sector read-through; this is company-specific holder activity rather than industry/regulatory change.

None.

None.

Counterpoint

A single affiliate sale at a fixed low price may reflect diversification or liquidity needs rather than bearish fundamentals, especially if other holders remain steady.

Key entities

  • Werewolf Therapeutics, Inc.

    Subject of the Form 4; ticker HOWL.

  • RA Capital Management, L.P.

    Reported indirect open-market sale of HOWL shares; no 10b5-1 plan indicated.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HOWLMedAI 8/10

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou